Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential

被引:3
|
作者
Voutsadakis, Ioannis A. [1 ,2 ]
机构
[1] Sault Area Hosp, Algoma Dist Canc Program, 750 Great Northern Rd, Sault Ste Marie, ON P6B 0A8, Canada
[2] Northern Ontario Sch Med, Div Clin Sci, Sect Internal Med, Sudbury, ON P3E 2C6, Canada
来源
MEDICINA-LITHUANIA | 2022年 / 58卷 / 10期
关键词
colon cancer; cell line models; dependencies; targeted therapy; signal transduction; GENOMIC LANDSCAPE; EXPRESSION; SPECIFICITY; ENCORAFENIB; ACTIVATION; CETUXIMAB; PATHWAY; ARK5;
D O I
10.3390/medicina58101498
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Colorectal cancer represents a common malignancy and remains incurable in the metastatic stage. Identification of molecular alterations that are present in colorectal cancer has led to the introduction of targeted therapies that improve outcomes. BRAF and PIK3CA mutations are observed in a subset of colorectal cancers. Colorectal cancers bearing BRAF mutations may be treated with specific BRAF inhibitors. These drugs benefit patients with BRAF mutant colorectal cancers but responses are rather brief, and progression is the rule. In contrast, no PI3K inhibitors have proven successful yet in the disease. Thus, new treatments to supplement the currently available drugs would be welcome to further improve survival. Methods: Profiled colorectal cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) were examined for BRAF and PIK3CA mutations and were interrogated for molecular characteristics and concomitant alterations that mirror clinical sample alterations. The Genomics of Drug Sensitivity in Cancer (GDSC) project was used for determination of drug sensitivities of BRAF mutated colorectal cell lines with or without concomitant PIK3CA mutations. The Cancer Dependency Map project served as the basis for identification of molecular dependencies and vulnerabilities in these cell lines. Results: CCLE includes 84 colorectal cancer cell lines, which recapitulate the molecular landscape of colorectal cancer. Of these, 23 and 24 cell lines possess BRAF and PIK3CA mutations, respectively. Seven BRAF mutant cell lines have V600E mutations and 14 PIK3CA mutant cell lines have hotspot helical or kinase domain mutations. V600E BRAF mutant cell lines with or without hotspot PIK3CA mutations are heterogeneous in their MSI status and mimic colorectal cancer tissues in other prevalent abnormalities including APC and TP53 mutations. Essential genes for survival include CTNNB1, WRN, and pyrimidine metabolism enzyme CAD. Besides BRAF mutations, BRAF inhibitor sensitivity in colorectal cancer cell lines is conferred by SACS mutations and PRKN locus loss. Conclusions: Colorectal cancer cell lines bearing the frequent BRAF and PIK3CA mutations present many alterations of the parental cancer tissue. Described vulnerabilities represent leads for therapeutic exploration in colorectal cancers with the corresponding alterations.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma
    Jin, Nan
    Keam, Bhumsuk
    Cho, Janice
    Lee, Michelle J.
    Kim, Hye Ryun
    Torosyan, Hayarpi
    Jura, Natalia
    Ng, Patrick Ks
    Mills, Gordon B.
    Li, Hua
    Zeng, Yan
    Barbash, Zohar
    Tarcic, Gabi
    Kang, Hyunseok
    Bauman, Julie E.
    Kim, Mi-Ok
    VanLandingham, Nathan K.
    Swaney, Danielle L.
    Krogan, Nevan J.
    Johnson, Daniel E.
    Grandis, Jennifer R.
    JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (22)
  • [32] PIK3CA Gene Mutations and Overexpression: Implications for Prognostic Biomarker and Therapeutic Target in Chinese Esophageal Squamous Cell Carcinoma
    Wang, Lin
    Shan, Ling
    Zhang, Shaokai
    Ying, Jianming
    Xue, Liyan
    Yuan, Yanling
    Xie, Yongqiang
    Lu, Ning
    PLOS ONE, 2014, 9 (07):
  • [33] PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance
    Santarpia, Mariacarmela
    Altavilla, Giuseppe
    Margeli, Mireia
    Cirauqui, Beatriz
    Mesiti, Mario
    Cavallari, Vittorio
    Ramirez, Jose Luis
    Sanchez-Ronco, Maria
    Santarpia, Libero
    Taron, Miquel
    Rosell, Rafael
    CANCER INVESTIGATION, 2008, 26 (10) : 1044 - 1051
  • [34] High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
    Guedes, Joana G.
    Veiga, Isabel
    Rocha, Patricia
    Pinto, Pedro
    Pinto, Carla
    Pinheiro, Manuela
    Peixoto, Ana
    Fragoso, Maria
    Raimundo, Ana
    Ferreira, Paula
    Machado, Manuela
    Sousa, Nuno
    Lopes, Paula
    Araujo, Antonio
    Macedo, Joana
    Alves, Fernando
    Coutinho, Camila
    Henrique, Rui
    Santos, Lucio L.
    Teixeira, Manuel R.
    BMC CANCER, 2013, 13
  • [35] Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells
    Zumwalt, Timothy J.
    Wodarz, Dominik
    Komarova, Natalia L.
    Toden, Shusuke
    Turner, Jacob
    Cardenas, Jacob
    Burn, John
    Chan, Andrew T.
    Boland, C. Richard
    Goel, Ajay
    CANCER PREVENTION RESEARCH, 2017, 10 (03) : 208 - 218
  • [36] Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine
    Shen, Yinchen
    Wang, Jianfei
    Han, Xiaohong
    Yang, Hongying
    Wang, Shuai
    Lin, Dongmei
    Shi, Yuankai
    PLOS ONE, 2013, 8 (12):
  • [37] KRAS, NRAS, PIK3CA Exon 20, and BRAF Genotypes in Synchronous and Metachronous Primary Colorectal Cancers Diagnostic and Therapeutic Implications
    Balschun, Katharina
    Haag, Jochen
    Wenke, Ann-Kathrin
    von Schoenfels, Witigo
    Schwarz, Nicolas T.
    Roecken, Christoph
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2011, 13 (04) : 436 - 445
  • [38] Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer
    Wu, Jing-Bo
    Li, Xiao-Jing
    Liu, Hui
    Liu, Yong-Juan
    Liu, Xiu-Ping
    BIOMEDICAL REPORTS, 2023, 19 (06)
  • [39] Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
    Nakayama, Izuma
    Shinozaki, Eiji
    Matsushima, Tomohiro
    Wakatsuki, Takeru
    Ogura, Mariko
    Ichimura, Takashi
    Ozaka, Masato
    Takahari, Daisuke
    Suenaga, Mitsukuni
    Chin, Keisho
    Mizunuma, Nobuyuki
    Yamaguchi, Kensei
    BMC CANCER, 2017, 17
  • [40] Landscape of KRAS, BRAF, and PIK3CA Mutations and Clinical Features of EBV-Associated and Microsatellite Unstable Gastric Cancer
    Danishevich, A. M.
    Pospehova, N. I.
    Stroganova, A. M.
    Golovina, D. A.
    Nikulin, M. P.
    Kalinin, A. E.
    Nikolaev, S. E.
    Stilidi, I. S.
    Lyubchenko, L. N.
    MOLECULAR BIOLOGY, 2023, 57 (01) : 61 - 73